PDF(Pubmed)
Abstract：
BACKGROUND: Periodontal regeneration faces multiple challenges, the most important being cellular insufficiency. In an attempt to improve defect cellularity, we aimed to demonstrate enhancing cellular attraction using arginine-glycine-aspartic acid (RGD) adhesion molecule legend blended hydrogel within the intrabony defects.
METHODS: Forty-five intrabony defects were selected from patients with stage III or IV - grade A or B periodontitis and divided randomly into three equal groups of 15 each: group1 (G1): received minimally invasive surgical technique (MIST) alone, group2 (G2): received MIST and placebo hydrogel injection, and group3 (G3): were treated with MIST and RGD hydrogel injection. Primary outcomes 6 months following therapy were; defect base fill (DBF) and defect width measurement (DW); secondary outcomes were clinical attachment level (CAL), pocket depth (PD), plaque index (PI), gingival index (GI), and biochemical analysis of bone morphogenetic protein (BMP-2) evaluated at 1,7,14 and 21 days following therapy.
RESULTS: Significant improvements in DBF, CAL, and PD were observed in the three studied groups 6 months following therapy compared to baseline (p<0.05). A significant improvement in DBF was reported in G3 compared to G1 and 2 (p=0.005). Additionally, a significantly higher CAL gain was reported in G3 compared to that of G1 (p=0.02). Group 3 was associated with a significantly higher level of BMP-2 compared to G1 and G2 in all reported periods.
CONCLUSIONS: RGD peptide carried on a hydrogel delivery agent and contained with a minimally invasive flap could be a reliable option in improving the outcomes of periodontal therapy.
METHODS: Forty-five intrabony defects were selected from patients with stage III or IV - grade A or B periodontitis and divided randomly into three equal groups of 15 each: group1 (G1): received minimally invasive surgical technique (MIST) alone, group2 (G2): received MIST and placebo hydrogel injection, and group3 (G3): were treated with MIST and RGD hydrogel injection. Primary outcomes 6 months following therapy were; defect base fill (DBF) and defect width measurement (DW); secondary outcomes were clinical attachment level (CAL), pocket depth (PD), plaque index (PI), gingival index (GI), and biochemical analysis of bone morphogenetic protein (BMP-2) evaluated at 1,7,14 and 21 days following therapy.
RESULTS: Significant improvements in DBF, CAL, and PD were observed in the three studied groups 6 months following therapy compared to baseline (p<0.05). A significant improvement in DBF was reported in G3 compared to G1 and 2 (p=0.005). Additionally, a significantly higher CAL gain was reported in G3 compared to that of G1 (p=0.02). Group 3 was associated with a significantly higher level of BMP-2 compared to G1 and G2 in all reported periods.
CONCLUSIONS: RGD peptide carried on a hydrogel delivery agent and contained with a minimally invasive flap could be a reliable option in improving the outcomes of periodontal therapy.
摘要：
背景：牙周再生面临多重挑战，最重要的是细胞功能不全。为了改善缺陷细胞数量，我们旨在证明使用精氨酸-甘氨酸-天冬氨酸（RGD）粘附分子图例混合水凝胶在骨内缺陷中增强细胞吸引力。
方法：从III期或IV期-A级或B级牙周炎患者中选择45例牙内缺损，随机分为3组，每组15例：第1组（G1）：仅接受微创手术技术（MIST）。组2（G2）：接受MIST和安慰剂水凝胶注射，第3组(G3):用MIST和RGD水凝胶注射治疗。治疗后6个月的主要结果是;缺损基底填充（DBF）和缺损宽度测量（DW）;次要结果是临床附着水平（CAL），口袋深度(PD),菌斑指数（PI），牙龈指数（GI），和骨形态发生蛋白（BMP-2）的生化分析在治疗后1、7、14和21天进行评估。
结果：DBF的显着改善，CAL,与基线相比，三个研究组在治疗后6个月观察到PD（p<0.05）。与G1和2相比，G3中的DBF显着改善（p=0.005）。此外,与G1相比，G3中的CAL增益明显更高（p=0.02）。在所有报告的时期中，第3组的BMP-2水平明显高于G1和G2。
结论：RGD肽携带在水凝胶递送剂上，并包含在微创皮瓣中，可能是改善牙周治疗结果的可靠选择。
方法：从III期或IV期-A级或B级牙周炎患者中选择45例牙内缺损，随机分为3组，每组15例：第1组（G1）：仅接受微创手术技术（MIST）。组2（G2）：接受MIST和安慰剂水凝胶注射，第3组(G3):用MIST和RGD水凝胶注射治疗。治疗后6个月的主要结果是;缺损基底填充（DBF）和缺损宽度测量（DW）;次要结果是临床附着水平（CAL），口袋深度(PD),菌斑指数（PI），牙龈指数（GI），和骨形态发生蛋白（BMP-2）的生化分析在治疗后1、7、14和21天进行评估。
结果：DBF的显着改善，CAL,与基线相比，三个研究组在治疗后6个月观察到PD（p<0.05）。与G1和2相比，G3中的DBF显着改善（p=0.005）。此外,与G1相比，G3中的CAL增益明显更高（p=0.02）。在所有报告的时期中，第3组的BMP-2水平明显高于G1和G2。
结论：RGD肽携带在水凝胶递送剂上，并包含在微创皮瓣中，可能是改善牙周治疗结果的可靠选择。
